Kyverna Therapeutics Common Stock logo

Kyverna Therapeutics Common StockNASDAQ: KYTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

Next earnings report:

29 November 2024

Last dividends:

N/A

Next dividends:

N/A
$181.32 M
-86%vs. 3y high
52%vs. sector
-vs. 3y high
-vs. sector
-83%vs. 3y high
30%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 00:49:42 GMT
$4.20-$0.42(-9.09%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

KYTX Latest News

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
prnewswire.com13 November 2024 Sentiment: POSITIVE

Multiple Key Leadership Appointments, Including Warner Biddle as CEO, Bringing Clinical, Commercial and Strategic Expertise in Cell Therapy Continuing to Advance Broad KYSA Clinical Development Program: Presented Clinical Data Highlighting Potential for KYV-101 in SPS, MG and MS at ECTRIMS and Plan to Share Updated Clinical Data in LN at Company Symposium at ACR Convergence 2024 Strong Financial Position; Ended the Quarter With $321.6 Million in Cash, Cash Equivalents and Marketable Securities EMERYVILLE, Calif. , Nov. 13, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the third quarter ended September 30, 2024.

Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
prnewswire.com21 October 2024 Sentiment: POSITIVE

Enriches Board's expertise in corporate strategy and business development, with vast experience leading biopharmaceutical companies through rapid growth and creating value across innovative therapeutic platforms, including cell therapy EMERYVILLE, Calif. , Oct. 21, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the appointment of biotechnology executive and cell therapy veteran Mert Aktar as an independent director to its Board of Directors.

Kyverna Therapeutics Announces Leadership Update
prnewswire.com16 September 2024 Sentiment: POSITIVE

– Warner Biddle Appointed as Chief Executive Officer and to Board of Directors, Bringing Over 30 Years of Commercial, Product Planning and Franchise Leadership Experience, Including Successful Launches for CAR T Pioneer in Hematology – Christi Shaw, Life Sciences Leader at Multiple Major Pharmaceutical and Biotech Companies and Across Therapeutic Areas, Appointed to Board of Directors – Together Strengthen Leadership as Trailblazers of Cell Therapy with Extensive Experience Leading Through Clinical Development, Manufacturing, Commercial Launch and Expansion EMERYVILLE, Calif. , Sept. 16, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the appointment of Warner Biddle as the Company's Chief Executive Officer (CEO) and a member of its Board of Directors.

The Schall Law Firm Is Looking Into Whether Kyverna Therapeutics Inc Committed Securities Fraud And Investors Should Join The Inquiry
accesswire.com05 September 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Kyverna Therapeutics Inc. May Have Violated Securities Regulations And The Schall Law Firm Wants Stakeholders With Losses To Reach Out
accesswire.com04 September 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Whether Kyverna Therapeutics Inc Committed Securities Fraud And Impacted Investors Are Urged To Play A Part
accesswire.com03 September 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Kyverna Therapeutics Inc. May Be Liable To Compensate Investors And Those With Losses Should Contact The Schall Law Firm About An Inquiry
accesswire.com02 September 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Wants The Public's Contributions To An Investigation Into Whether Kyverna Therapeutics Inc Committed Securities Fraud
accesswire.com01 September 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Kyverna Therapeutics Inc. Is Being Looked Into For Committing Securities Law Infractions And Stakeholders Are Invited To Help The Schall Law Firm
accesswire.com31 August 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

A Securities Fraud Inquiry Has Been Launched Into Kyverna Therapeutics Inc And The Schall Law Firm Is Seeking Investor Participation
accesswire.com30 August 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

  • 1(current)
  • 2
  • 3

What type of business is Kyverna Therapeutics Common Stock?

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

What sector is Kyverna Therapeutics Common Stock in?

Kyverna Therapeutics Common Stock is in the Healthcare sector

What industry is Kyverna Therapeutics Common Stock in?

Kyverna Therapeutics Common Stock is in the Biotechnology industry

What country is Kyverna Therapeutics Common Stock from?

Kyverna Therapeutics Common Stock is headquartered in United States

What is Kyverna Therapeutics Common Stock website?

https://kyvernatx.com

Is Kyverna Therapeutics Common Stock in the S&P 500?

No, Kyverna Therapeutics Common Stock is not included in the S&P 500 index

Is Kyverna Therapeutics Common Stock in the NASDAQ 100?

No, Kyverna Therapeutics Common Stock is not included in the NASDAQ 100 index

Is Kyverna Therapeutics Common Stock in the Dow Jones?

No, Kyverna Therapeutics Common Stock is not included in the Dow Jones index

When was Kyverna Therapeutics Common Stock the previous earnings report?

No data

When does Kyverna Therapeutics Common Stock earnings report?

The next expected earnings date for Kyverna Therapeutics Common Stock is 29 November 2024